We are live on ! Find out more
VRPX

Virpax Pharmaceuticals, Inc. Common Stock
VRPX

Delisted

VRPX was delisted on the 3rd of April, 2025.

Back to rankings

14 hedge funds and large institutions have $874K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less capital invested

Capital invested by funds: $973K → $874K (-$99.2K)

22% less funds holding

Funds holding: 18 → 14 (-4)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
14
Holders Change
-4
Holders Change %
-22.22%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$223

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$256K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$100K
3
Citadel Advisors
Citadel Advisors
Florida
-$9.09K
4
E
Ergoteles
New York
-$7.89K
5
UBS Group
UBS Group
Switzerland
-$7.35K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$551K -$256K -1,147 -29%
PNC Financial Services Group
2
PNC Financial Services Group
Pennsylvania
$79.2K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$75K -$893 -4 -1%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$51.6K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$51.1K -$100K -450 -63%
BAM
6
Belpointe Asset Management
Nevada
$14.9K – – –
WAM
7
Warberg Asset Management
Illinois
$13.4K – – –
Cambridge Investment Research Advisors
8
Cambridge Investment Research Advisors
Iowa
$13K -$446 -2 -3%
Northern Trust
9
Northern Trust
Illinois
$11.9K – – –
QPW
10
Quantum Private Wealth
Florida
$7.85K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$4K +$223 +1 +5%
Osaic Holdings
12
Osaic Holdings
Arizona
$471 – – –
BlackRock
13
BlackRock
New York
$364 – – –
Morgan Stanley
14
Morgan Stanley
New York
$118 -$670 -3 -75%
ASN
15
Advisory Services Network
Georgia
$97 – – –
Wells Fargo
16
Wells Fargo
California
$47 – – –
Citadel Advisors
17
Citadel Advisors
Florida
– -$9.09K -58 Closed
E
18
Ergoteles
New York
– -$7.89K -51 Closed
UBS Group
19
UBS Group
Switzerland
– -$7.35K -47 Closed
SG
20
StoneX Group
New York
– -$7.22K -46 Closed

VRPX Hedge Fund Activity: Q1 2023 in Review

14 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q1 2023, worth a combined $874K — down 10% from $973K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of VRPX and 0 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $223. The largest seller was Sabby Management, cutting an estimated $256K.

  • 14 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q1 2023, down from 18 in Q4 2022.
  • Funds reported $874K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 10% quarter-over-quarter.
  • 0 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 4 closed out, a net change of -4 holders.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $223 added.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Sabby Management, an estimated $256K sold.

Based on aggregated 13F filings for Q1 2023.